Sara Tinsley, PhD, APRN, AOCN, on MDS: Pevonedistat and Azacitidine for Higher-Risk Disease
Sara Tinsley, PhD, APRN, AOCN, of Moffitt Cancer Center, discusses what advanced practitioners need to understand about the findings on safety and efficacy of pevonedistat plus azacitidine vs azacitidine alone in patients with higher-risk myelodysplastic syndromes (Abstract 653).
